Importantly, the pro-tumorigenic role of LPS/TLR4/NF-κB signaling extends beyond colorectal cancer, with demonstrated significance in bone cancer, hepatocellular carcinoma, and ovarian cancer, highlighting its broad relevance as a therapeutic target across malignancies (36–38). This evidence concerns the gene TLR4 and bone neoplasm.